Another day, another win for Enhertu.
The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on has had a quite a few months, beginning with splashy results in a Phase II breast cancer trial, a rapid approval and, earlier this month, breakthrough designations in both non-small cell lung cancer and gastric cancer.
Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy. Progression-free survival was 5.4 months for Enhertu compared to 3.5 months for the control.
"continued" - Google News
May 29, 2020 at 06:22PM
https://ift.tt/3enuTsS
Sanofi brings in 4 new executives in continued shake-up, as vaccines and consumer health chief head out the door - Endpoints News
"continued" - Google News
https://ift.tt/2WiTaZN
https://ift.tt/2YquBwx
Bagikan Berita Ini
0 Response to "Sanofi brings in 4 new executives in continued shake-up, as vaccines and consumer health chief head out the door - Endpoints News"
Post a Comment